Business Context and Reporting Period
Company: NETWORK-1 TECHNOLOGIES, INC. (NTIP)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Model: The Company develops, licenses, and protects intellectual property assets, primarily through patent portfolios covering M2M/IoT, High Frequency Trading (HFT), media content identification (Cox), and Smart Home technologies. The Company also holds an equity investment in ILiAD Biotechnologies, Inc.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $150,000 |
| Operating Expenses | $1,415,000 | $795,000 |
| Operating Loss | $(1,415,000) | $(645,000) |
| Net Loss | $(511,000) | $(363,000) |
| Net Loss Per Share (Basic/Diluted) | $(0.02) | $(0.02) |
| Cash and Cash Equivalents | $8,610,000 | $12,288,000 (End of Q1 2025) |
| Marketable Securities | $25,979,000 | $23,467,000 (Dec 31, 2025) |
| Total Assets | $39,393,000 | $40,332,000 (Dec 31, 2025) |
| Working Capital | $33,674,000 | $36,336,000 (Dec 31, 2025) |
| Dividends Declared Per Share | $0.05 | $0.05 |
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped to $0 from $150,000 in Q1 2025 due to the absence of litigation settlements or licensing fees in the current quarter.
- Operating Expense Increase: Operating expenses rose by $620,000 (78% increase), driven primarily by a $625,000 increase in litigation-related professional fees.
- Gain on Equity Investment: The Company recorded a non-cash gain of $1,052,000 on its investment in ILiAD Biotechnologies, Inc. This resulted from ILiAD's Series B financing in February 2026, which triggered a remeasurement of the investment and a change in accounting from the equity method to the cost method.
- Net Loss Increase: Despite the $1.052M gain, the Net Loss increased to $511,000 from $363,000. This was due to the loss of revenue, higher litigation costs, a $287,000 loss on marketable securities (vs. $149,000 gain prior year), and a $245,000 deferred tax expense.
- Cash Flow: Net cash used in operating activities was $310,000, compared to $159,000 provided by operating activities in Q1 2025. Investing activities used $3.248M primarily for the purchase of marketable securities.
Guidance, Outlook, and Risks
- Outlook: Future revenue depends on monetizing patent portfolios (M2M/IoT, HFT, Cox, Smart Home) and the outcome of pending litigations. Management anticipates continuing semi-annual dividends of $0.05 per share, subject to Board review.
- Legal Proceedings:
- Google/YouTube: The Federal Circuit overturned a lower court's non-infringement judgment regarding the Company's '237 Patent, remanding the case for further proceedings.
- Samsung: The PTAB denied Samsung's requests for Inter Partes Review on all six asserted patents in the ongoing litigation.
- HFT Litigation: Active suits against Optiver, Citadel Securities, and Jump Trading are ongoing.
- Risks:
- Personal Holding Company (PHC): The Company faces potential classification as a PHC in 2026, which could trigger a 20% tax on undistributed income, potentially requiring a special cash dividend.
- Litigation Uncertainty: Revenue is contingent on successful litigation outcomes or licensing agreements.
- Investment Risk: The return on the ILiAD investment is uncertain and dependent on the biotech company's clinical success and future financing.
Investor Verification Checklist
- Revenue Visibility: Verify the status of the five pending litigations (Samsung, Optiver, Citadel, Jump, Google) as these are the primary drivers for future revenue.
- ILiAD Investment Status: Confirm the valuation methodology for the ILiAD investment under the new cost method and monitor for future observable price changes.
- PHC Tax Status: Monitor shareholder ownership concentration and income composition to assess the risk of Personal Holding Company tax liability in 2026.
- Liquidity Runway: Confirm that the $34.6M in cash and marketable securities is sufficient to fund operations and litigation costs given the lack of operating revenue.
- Dividend Sustainability: Assess whether the Company can maintain its $0.10 annual dividend policy amidst increased operating expenses and potential PHC tax obligations.